Email This Article

Health Stocks in Motion
By Mark Martinez
01/12/05 - 04:38 PM EST
Myriad Genetics rises on phase III advancement of its Alzheimer's drug.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,406.96 1,109.30 2,197.85 33.31
Oil *
78.75
UP
136.49
UP
15.82
UP
29.97
DOWN
0.98
10 Yr
3.33%
SPDR Gold
111.63
+1.33%
+1.45%
+1.38%
-2.86%
Data delayed 20 minutes

Brokerage Partners